Paris, France-based clinical-stage biopharmaceutical company specialized in the development of microbiome-based immunotherapies with a mission to bring innovation to the treatment of inflammatory bowel diseases, cancer, and infectious diseases, Exeliom Bioscience, closed its Series A financing at EUR 24 million. The round took place on July 3, 2023.
New international VC investors, such as the corporate venture capital platform of Crescent Enterprises, CE-Ventures, led the EUR 8 million Series A extension. Existing investors such as VCs Auriga Partners and UI Investissement, and Biocodex, an independent multinational pharmaceutical company, provided the funds.
The company earlier raised EUR 7 million in 2018. It further secured a first extension of EUR 3 million in 2021. In addition, the company received EUR 6 million in non-dilutive funding secured over the period.
Purpose of financing for Exeliom Bioscience
With the latest proceeds from Series A, the company seeks to progress the clinical development of its therapeutic pipeline. It includes several clinical trials of EXL01, a novel immunotherapy with applications in cancer and in infectious diseases.
The company also has plans to launch, in parallel, a Phase 1/2 study evaluating EXL01. It will act as an alternative to the current standard treatment (faecal transplantation) for recurrent Clostridium difficile infection.
What the company’s official has to add
Benjamin, Hadida, Chief Executive Officer of Exeliom Biosciences, said, “We are very pleased to receive the funding and strong support from our current financial partners and a new investor, CE-Ventures. They recognized our ability to open a new chapter in microbiome-based immunotherapy. Already evaluated for Crohn’s disease, our lead candidate, EXL01, based on a unique strain of F. prausnitzii, demonstrated synergistic effects with immune checkpoint inhibitors, thanks to its immuno-modulatory properties, paving the way for promising therapeutic effects in immuno-oncology. EXL01 could be the next-generation product for the treatment of recurrent C. difficile infection to replace donor-derived faecal matter transplant products. We now have the resources to build an ambitious pipeline-in-a-drug strategy. We look forward to starting our first additional clinical trials in early 2024”.
What the investors have to add
Tushar Singhvi, Deputy CEO and Head of Investments, Crescent Enterprises, further added, “CE-Ventures is highly aware of the transformative potential that innovative fields, such as microbiome, hold. It represents a frontier of scientific discovery and therapeutic potential, which we firmly believe has the power to reshape healthcare as we know it. Our investment in this sector is guided by the conviction that understanding and leveraging the microbiome could unlock significant improvements in human health and well-being.” He added: “In our quest to support pioneers in this field, Exeliom Biosciences is a valuable partner, offering a differentiated approach in the field of immuno-oncology and infectious diseases. Their work is not just about creating marketable solutions; it is about making a meaningful, lasting impact. Our partnership signifies our commitment to investing in the future – a future where scientific innovation and health converge to improve lives on a global scale.”
About Exeliom Bioscience
Prof. Harry Sokol, Dr Philippe Langella and Prof. Patrick Gervais launched the company in 2016. The company aims to revolutionize the treatment of inflammatory bowel diseases, cancer, and infectious diseases.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
